Agios Pharmaceuticals (AGIO) Total Current Liabilities (2012 - 2026)

Agios Pharmaceuticals has reported Total Current Liabilities for 15 years, with the latest figure at $58.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 12.37% year-over-year to $58.8 million; the trailing twelve-month figure through Mar 2026 stood at $58.8 million (up 12.37% YoY), and the FY2025 full-year result was $82.2 million, up 1.29% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $58.8 million, down from $82.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $119.5 million in Q3 2024, with the low at $45.1 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $64.2 million across 5 years, with a median of $58.8 million in 2026.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 52.55% — and 2024, when it surged 104.45%.
• Agios Pharmaceuticals' Total Current Liabilities stood at $62.6 million in 2022, then advanced by 8.5% to $68.0 million in 2023, then increased by 19.43% to $81.2 million in 2024, then advanced by 1.29% to $82.2 million in 2025, then slipped by 28.42% to $58.8 million in 2026.
• The last three Total Current Liabilities figures came in at $58.8 million (Q1 2026), $82.2 million (Q4 2025), and $74.8 million (Q3 2025), per Business Quant data.